BS01™ + LR04 + LP02 (BIFIMMUN)
Allergy & Immunology
Immune stimulation / Respiratory tract infections
Reinforces the body’s natural defenses
Reduces intestinal discomfort
Inhibits intestinal and respiratory pathogens
1) BS01 10 billion CFU + LR04 10 billion CFU + LP02 10 billion CFU + FOS
Single strain
Blend
Finished dosage form
1) Pregliasco F. et al. A New Chance of Preventing Winter Diseases by the Administration of Symbiotic Formulations. Journal of Clinical Gastroenterology, 2008; 42(2): 224-233. DOI: 10.1097/MCG.0b013e31817e1c91
a) Mogna L. et al. Micronized Cells of the Probiotic Strain Bifidobacterium lactis BS01 Activate Monocyte Polarization: A New Approach. J Clin Gastroenterol. 2018;52:S57-S61.doi: 10.1097/MCG.0000000000001068
b) Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J. Clin. Gastroenterol. 2012;46 Suppl.S29-32. Doi: 10.1097/MCG.0b013e31826852b7
c) Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216. DOI: 10.35248/2329-8901.20.8.216
d) Visciglia A. et al. Probiotics: a potential therapeutic strategy in respiratory infections. Poster from the 12th Probiotics, Prebiotics & New Foods, Nutraceutical and Botanicals for Nutrition & Human and Microbiota Health, held in Rome on 12-14 September 2021
